Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
Titel:
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
Auteur:
Rovin, Brad H Barratt, Jonathan Heerspink, Hiddo J L Alpers, Charles E Bieler, Stewart Chae, Dong-Wan Diva, Ulysses A Floege, Jürgen Gesualdo, Loreto Inrig, Jula K Kohan, Donald E Komers, Radko Kooienga, Laura Ann Lafayette, Richard Maes, Bart Małecki, Robert Mercer, Alex Noronha, Irene L Oh, Se Won Peh, Chen Au Praga, Manuel Preciado, Priscila Radhakrishnan, Jai Rheault, Michelle N Rote, William E Tang, Sydney C W Tesar, Vladimir Trachtman, Howard Trimarchi, Hernán Tumlin, James A Wong, Muh Geot Perkovic, Vlado